Light-Based blood test may spot lung cancer early
NCT ID NCT07755020
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This study is testing a new device called a nitride-based Raman biochip that analyzes blood samples using light to detect molecular patterns linked to lung cancer. Researchers will compare results from 2,000 people with lung cancer and 1,000 without to see if the test can accurately tell the two groups apart. The goal is to find a less invasive way to help diagnose and monitor lung cancer, potentially complementing current methods like CT scans and biopsies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Nitride-based Raman biochip (a blood test device that analyzes molecular patterns)
- What this could lead to
- If successful, this could provide a simple blood test to help detect lung cancer earlier and monitor the disease over time, potentially reducing the need for invasive biopsies.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly change patient outcomes. The test's accuracy is still being evaluated, and it may not prove reliable enough for widespread clinical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Dec 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients receiving clinical care at Taichung Veterans General Hospital, Far Eastern Memorial Hospital, or Taoyuan General Hospital, Ministry of Health and Welfare, who underwent low-dose computed tomography or chest computed tomography within the previous two years. The study population will include participants with pathologically confirmed lung cancer and participants without lung cancer who meet the radiological eligibility criteria.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Lung Cancer Group: 1. Age 18 years or older. 2. Underwent low-dose computed tomography or chest computed tomography within the previous 2 years. 3. Pathologically confirmed lung cancer. 4. Histological diagnosis of adenocarcinoma, squamous cell carcinoma, or small cell lung cancer, with TNM stage determined by a thoracic physician. 5. Willing to provide approximately 20 mL of peripheral blood annually for 3 years. 6. Able to understand the study information and provide written informed consent. 7. Agrees to linkage of study data with relevant health insurance and mortality databases, as applicable. Non-Lung Cancer Group: 1. Age 18 years or older. 2. Underwent low-dose computed tomography or chest computed tomography within the previous 2 years. 3. No pulmonary nodule or ground-glass lesion, or a pulmonary nodule or ground-glass lesion smaller than 0.4 cm. 4. May have a chronic pulmonary disease, including chronic obstructive pulmonary disease, asthma, bronchiectasis, or pulmonary fibrosis. 5. Willing to provide one peripheral blood sample of approximately 20 mL. 6. Able to understand the study information and provide written informed consent. 7. Agrees to linkage of study data with relevant health insurance and mortality databases, as applicable. Exclusion Criteria: * 1\. Younger than 18 years of age. 2. Unable to understand the study information or provide written informed consent. 3\. For the non-lung cancer group, presence of a pulmonary nodule or ground-glass lesion greater than 0.4 cm. 4\. Unwilling to provide a peripheral blood sample. 5. Unwilling to permit linkage with the National Health Insurance research data system.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer (diagnosis) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Taichung Veterans General Hospital
RECRUITINGTaichung, 407219, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI tailor recovery instructions after lung cancer surgery?
- Can a new radiation machine cut breath holds for cancer patients?
- Which nerve block wins for lung surgery pain?
- Software aims to steer bronchoscopes more precisely in lung cancer checks
- Radiation and immunotherapy combo tested against advanced lung cancer
- Radioactive antibody aims to light up hidden solid tumors